Management of Occupational and Nonoccupational HIV Exposure

  • Author: Christopher B. Hurt, MD (More Info)
  • Editors In Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 8/1/18 (What's New)

Summary

  • PEP failures significant because of likelihood that antiretroviral resistance mutations will develop as result of drug exposure
  • Among 2-drug regimens, lamivudine-associated M184V resistance mutation earliest to develop
    • Timing of additional mutations depends on how long patient allowed to remain on treatment after M184V emerges

Action required

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.